Breaking News

Orna Therapeutics Acquires ReNAgade Therapeutics

Will combine its circular RNA expression technology with ReNAgade's portfolio of LNP-based RNA delivery systems and editing programs.

Author Image

By: Charlie Sternberg

Associate Editor

Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNA), has acquired ReNAgade Therapeutics, a pioneer in unlocking the potential of RNA therapeutics.   Amit D. Munshi, Chief Executive Officer of ReNAgade, will succeed Tom Barnes, Ph.D., to lead Orna as Chief Executive Officer.   “RNA-centric approaches are poised to eclipse traditional cell therapy-based methods and reshape the future of medicine...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters